Quick Answer
Vivos Therapeutics, Inc. reported Total Revenue of $15.03 million for the year ending 2024.
- Vivos Therapeutics, Inc. showed an increase of +8.9% in Total Revenue from 2023 to 2024.
- This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $3.20 million | Q2 2020: $3.27 million | Q3 2020: $3.29 million | Q1 2021: $3.45 million | Q2 2021: $4.50 million | Q3 2021: $4.55 million | Q1 2022: $3.64 million | Q2 2022: $4.18 million | Q3 2022: $4.25 million | Q1 2023: $3.86 million | Q2 2023: $3.40 million | Q3 2023: $3.30 million | Q1 2024: $3.42 million | Q2 2024: $4.05 million | Q3 2024: $3.86 million | Q1 2025: $3.02 million | Q2 2025: $3.82 million | Q3 2025: $6.78 million.
- Over the full 6 years of available data (2019 to 2024), Vivos Therapeutics, Inc.'s Total Revenue has grown by 31.9%.
- Historical annual values: Fiscal year 2024: $15.03 million | Fiscal year 2023: $13.80 million | Fiscal year 2022: $16.02 million | Fiscal year 2021: $16.89 million | Fiscal year 2020: $13.07 million | Fiscal year 2019: $11.39 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: